Roman Fabbricatore

Articles

Sacituzumab Govitecan Fails to Meet Primary PFS End Point in First-Line HR+/HER2– mBC

December 10th 2025

Sacituzumab govitecan did not improve PFS per BICR vs chemotherapy after endocrine therapy in hormone-receptor–positive/HER2-negative breast cancer.

Giredestrant Improves iDFS Compared With Endocrine Therapy in ER+, HER2– Breast Cancer

December 10th 2025

Giredestrant improved invasive disease-free survival vs endocrine therapy in ER-positive, HER2-negative, medium- and high-risk early breast cancer.

MK-1045 Therapy Proves Active, Safe With Dose Modification in Relapsed/Refractory ALL

December 9th 2025

The safety profile associated with MK-1045 administration was manageable with dose interruption and standard medical care.

Ziftomenib Plus Venetoclax and Azacitidine Is Tolerable and Active in NPM1/KMT2A+ AML

December 8th 2025

Ziftomenib plus venetoclax and azacitidine was safe and effective in patients with relapsed/refractory AML harboring NPM1 mutations or KMT2A rearrangements.

Zanzalintinib Plus Atezolizumab Improves OS in Previously Treated Metastatic CRC

October 20th 2025

Zanzalintinib plus atezolizumab demonstrate potential chemotherapy-free option in previously treated metastatic CRC.

Telisotuzumab Adizutecan Demonstrates Activity, Tolerability in Locally Advanced/Metastatic PDAC

October 20th 2025

Telisotuzumab adizutecan displayed early activity in locally advanced/metastatic PDAC.

Atezolizumab Plus Chemotherapy Demonstrates Noninferior Survival Vs Chemotherapy Alone in Advanced/Recurrent Endometrial Cancer

October 19th 2025

The addition of atezolizumab to chemotherapy demonstrated noninferior survival vs chemotherapy alone in advanced or recurrent endometrial cancer.

Regorafenib Plus Nivolumab Yields Nonsuperior Survival in Refractory Gastric/GEJ Cancer

October 17th 2025

regorafenib/nivolumab may encourage a search for more non-chemotherapy combinations for gastric cancer.

Belantamab Mafodotin Shows Single-Agent Activity in Relapsed/Refractory Multiple Myeloma

September 20th 2025

Belantamab mafodotin monotherapy was active and safe in patients with relapsed/refractory multiple myeloma.

Eque-Cel Demonstrates Activity in R/R Multiple Myeloma

September 19th 2025

Eque-cel was effective for the treatment of patients with relapsed/refractory multiple myeloma.

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, Newly Diagnosed Myeloma

September 17th 2025

Early and promising efficacy was shown with elranatamab added to daratumumab/lenalidomide in transplant-ineligible, newly diagnosed multiple myeloma.

Adjuvant Nivolumab Plus Chemo Decreases Disease Relapse Rates vs Chemo in Resected NSCLC

September 8th 2025

Adjuvant nivolumab plus chemotherapy led to a clinically meaningful reduction in relapse rates vs chemotherapy in resected NSCLC.

Mosunetuzumab Demonstrates High Response Rates in Treatment-Naive MZL

September 5th 2025

Frontline treatment with mosunetuzumab showed high antitumor activity in patients with marginal zone lymphoma regardless of risk status.

SC Daratumumab Prolongs PFS in High-Risk Smoldering Myeloma

September 5th 2025

Subcutaneous daratumumab monotherapy demonstrated a 24-month PFS rate of 79.9% in patients with high-risk smoldering multiple myeloma.

Belzutifan Prolongs Quality-Adjusted Time Without Symptoms or Toxicity in Advanced RCC

July 18th 2025

Treatment with belzutifan increased the time without progression or toxicity vs everolimus in patients with advanced RCC.

BGB-16673 Displays a High ORR and Tolerability in Waldenström Macroglobulinemia

June 19th 2025

BGB-16673 was safe and effective for the treatment of patients with relapsed/refractory Waldenström Macroglobulinemia.

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

June 16th 2025

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

RET Inhibitor Rechallenge Demonstrates Activity in Previously Treated NSCLC

June 8th 2025

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

Machine Learning–Based Approach Improves Outcome Prediction vs Individual Biomarkers in RCC

June 5th 2025

The evaluation of diverse biomarkers via a machine learning approach demonstrated improved prediction of clinical outcomes vs individual biomarkers in RCC.

CAN-2409 Plus EBRT Bests EBRT Alone in High-Risk Localized Prostate Cancer

June 3rd 2025

CAN-2409 plus prodrug and radiation therapy significantly improved DFS vs radiation therapy alone in intermediate-to-high-risk prostate cancer.